Affiliation:
1. Mental Health Research Centre
Abstract
The aim of the study is to evaluate the activity of platelet glutamate dehydrogenase (GDH) in late-life depression compared to the healthy control group and to reveal possible correlations with clinical data. Patients and methods: 42 elderly patients (60–86 years old) with depressive episodes of different nosological categories according to ICD-10 were examined: a single depressive episode (F32.0, F32.1), a depressive episode in recurrent depressive disorder (RDD — F33.0, F33.1) and a depressive episode in bipolar affective disorder (BD — F31.3). The activity of GDH and the severity of depression (using the Hamilton depressive scale, HAMD-17, and the Hamilton scale for assessing anxiety, HARS) were evaluated twice: before the starting the course of antidepressant therapy (day 0) and on the 28th day of the treatment course. Results: patients showed a significant decrease in the activity of GDH compared to the control group (p < 0.0008). Before the treatment, GDH activity was significantly reduced compared to the control in both RDD and BD (p < 0.002 and p < 0.004), whereas after the treatment, the decreased GDH activity was observed only in patients with BD (p < 0.002). When compared with the control group, male patients showed a significant decrease in GDH activity both before and after the treatment course (p < 0.017 and p < 0.027), whereas women patients showed the decrease only before the treatment (p < 0.014). Conclusion: the decreased platelet GDH activity in elderly depressions may indicate an impairment of glutamate metabolism. Gender differences were revealed in the reversal of GDH activity level after the therapy: in men, the level of GDH activity did not recover to control values after the treatment course. An elevation in the level of GDH to control values over a 28-day course of therapy occurred only in patients with RDD, but not in patients with BD.
Publisher
Medical Informational Agency Publishers
Reference16 articles.
1. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036
2. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238–249. https://doi.org/10.1038/nm.4050
3. Witkin JM, Knutson DE, Rodriguez GJ, Shi S. Rapid-Acting Antidepressants. Curr Pharm Des. 2018;24(22):2556–2563. https://doi.org/10.2174/1381612824666180730104707
4. Mosolov SN, Fedorova EYu. Novyi vzglyad na patogenez depressii: vozmozhno li poyavlenie bystrodeistvuyushchikh antidepressantov? Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;3:2–10. https://doi.org/10.21265/PSYPH.2020.79.58.001 Mosolov SN, Fedorova EYu. A Fresh Approach to the Pathogenesis of Depression: Is the Appearance of Rapid Acting Antidepressants Possible? Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;3:2–10. (In Russ.). https://doi.org/10.21265/PSYPH.2020.79.58.001
5. Smith HQ, Li C, Stanley CA, Smith TJ. Glutamate dehydrogenase, a complex enzyme at a crucial metabolic branch point. Neurochem Res. 2019;44(1):117–132. https://doi.org/10.1007/s11064-017-2428-0
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献